Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 3:23 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1129–1152 of 3,164 matching trials from the live ClinicalTrials.gov search.

Filters: San Antonio, Texas Clear all

Conditions: Chronic Kidney Disease, Sarcopenia
Interventions: Valine, EEA; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 45 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Osteoarthritis
Interventions: tanezumab, Placebo; Biological · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 97
States / cities: Jonesboro, Arkansas • Aurora, Colorado • Centennial, Colorado + 42 more

Conditions: Cardiogenic Shock, Acute Decompensated Heart Failure
Interventions: Impella 5.5; Device
Lead sponsor: Abiomed Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,017 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 15
States / cities: Los Angeles, California • Orlando, Florida • Tampa, Florida + 11 more

Conditions: Lymphoma, Acute Lymphoblastic Leukemia
Interventions: Apixaban, No systemic anticoagulant prophylaxis; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 1 Year to 17 Years
Enrollment: 512 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 64
States / cities: Phoenix, Arizona • Duarte, California • Loma Linda, California + 56 more

Conditions: Alzheimer Disease
Interventions: Gantenerumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: Not listed
Enrollment: 1,382 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 67
States / cities: Phoenix, Arizona • Sun City, Arizona • Fayetteville, Arkansas + 58 more

Conditions: Traumatic Amputation of Lower Extremity
Interventions: Not listed
Lead sponsor: Major Extremity Trauma Research Consortium; Other
Eligibility: 18 Years to 60 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 10
States / cities: San Francisco, California • Tampa, Florida • Baltimore, Maryland + 7 more

Conditions: Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Copanlisib Hydrochloride, Durvalumab, Echocardiography Test, Magnetic Resonance Imaging, Olaparib, X-Ray Imaging; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 17
States / cities: Buena Park, California • Los Angeles, California • Newport Beach, California + 10 more

Conditions: Solid Tumor Malignancies
Interventions: KQB548; Drug
Lead sponsor: Kumquat Biosciences Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 13
States / cities: La Jolla, California • Los Angeles, California • Denver, Colorado + 10 more

Conditions: Chronic Spontaneous Urticaria
Interventions: barzolvolimab, Matching placebo; Biological
Lead sponsor: Celldex Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 976 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 63
States / cities: Cullman, Alabama • Litchfield Park, Arizona • Scottsdale, Arizona + 47 more

Conditions: Bladder Cancer
Interventions: gemcitabine hydrochloride; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years to 120 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 98
States / cities: Little Rock, Arkansas • Los Angeles, California • Leesburg, Florida + 56 more

Conditions: Recurrent Large Cell Lung Carcinoma, Recurrent Lung Adenocarcinoma, Recurrent Squamous Cell Lung Carcinoma, Stage IV Large Cell Lung Carcinoma, Stage IV Lung Adenocarcinoma, Stage IV Squamous Cell Lung Carcinoma
Interventions: Bevacizumab, Carboplatin, Cetuximab, Laboratory Biomarker Analysis, Paclitaxel; Biological · Drug · Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 1,333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2022
U.S. locations: 797
States / cities: Anniston, Alabama • Mobile, Alabama • Anchorage, Alaska + 473 more

Conditions: Cervical Degenerative Disc Disease
Interventions: Cervical Artificial Disc (Advent™ Cervical Disc), Hallmark™ Anterior Cervical Plate System; Device
Lead sponsor: Orthofix Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 13
States / cities: Sacramento, California • Boulder, Colorado • Tampa, Florida + 10 more

Conditions: Small Cell Lung Cancer Metastatic or Locally Advanced, Neuroendocrine Cancer, Metastatic Neuroendocrine Prostate Cancer, Metastatic Advanced Poorly Differentiated Gastroenteropancreatic Neuroendocrine Carcinoma, Metastatic Advanced Merkel Cell Carcinoma, Locally Advanced Large Cell Neuroendocrine Carcinoma of the Lung, Locally Advanced Extrapulmonary Neuroendocrine Carcinoma, Locally Advanced Neuroendocrine Prostate Cancer, Locally Advanced Poorly Differentiated Gastroenteropancreatic Neuroendocrine, Locally Advanced Merkel Cell Carcinoma, Metastatic Large Cell Neuroendocrine Carcinoma of the Lung
Interventions: BL-M14D1; Drug
Lead sponsor: SystImmune Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 25
States / cities: Huntsville, Alabama • Glendale, California • Long Beach, California + 19 more

Conditions: Lymphoma
Interventions: asparaginase, cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, doxorubicin hydrochloride, leucovorin calcium, mercaptopurine, methotrexate, prednisone, thioguanine, vincristine sulfate, radiation therapy; Drug · Radiation
Lead sponsor: Children's Oncology Group; Network
Eligibility: 1 Year to 30 Years
Enrollment: 393 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2015
U.S. locations: 152
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 127 more

Conditions: Gastroesophageal Reflux Disease (GERD)
Interventions: IW-3718, placebo, Standard-dose PPIs QD; Drug
Lead sponsor: Ironwood Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 609 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 98
States / cities: Birmingham, Alabama • Dothan, Alabama • Peoria, Arizona + 81 more

Conditions: Idiopathic Parkinson's Disease
Interventions: Safinamide (as add-on therapy); Drug
Lead sponsor: Newron Pharmaceuticals SPA; Industry
Eligibility: 30 Years to 80 Years
Enrollment: 679 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 31
States / cities: Birmingham, Alabama • Phoenix, Arizona • Oxnard, California + 27 more

Conditions: Dravet Syndrome
Interventions: LP352, Placebo; Drug
Lead sponsor: Longboard Pharmaceuticals; Industry
Eligibility: 2 Years to 65 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 25
States / cities: Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 20 more

Conditions: Contraception
Interventions: Relugolix Combination Therapy; Drug
Lead sponsor: Sumitomo Pharma Switzerland GmbH; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 1,164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 109
States / cities: Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 89 more

Conditions: Recurrent Renal Cell Carcinoma, Stage IV Renal Cell Cancer
Interventions: Vorinostat; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 2
States / cities: San Antonio, Texas

Conditions: Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions: Biopsy Procedure, Biospecimen Collection, Capecitabine, Computed Tomography, Dose-escalated Radiation Therapy, Fluorouracil, Gemcitabine, Irinotecan Hydrochloride, Irinotecan Sucrosofate, Leucovorin Calcium, Magnetic Resonance Imaging, Nab-paclitaxel, Observation Activity, Oxaliplatin, Positron Emission Tomography, Questionnaire Administration, Radiation Therapy, Tumor Treating Fields Therapy; Procedure · Drug · Radiation + 1 more
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older
Enrollment: 356 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 332
States / cities: Gilbert, Arizona • Peoria, Arizona • Phoenix, Arizona + 252 more

Conditions: Multiple Myeloma
Interventions: Fluphenazine HCl; Drug
Lead sponsor: Immune Control; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 3
States / cities: Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania • San Antonio, Texas

Conditions: Cardiovascular Disease
Interventions: Olpasiran, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 50 Years to 105 Years
Enrollment: 11,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 205
States / cities: Alexander City, Alabama • Birmingham, Alabama • Daphne, Alabama + 170 more

Conditions: Myelofibrosis (MF)
Interventions: Ruxolitinib, Navitoclax; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 191 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 33
States / cities: Birmingham, Alabama • Cerritos, California • Duarte, California + 27 more

Conditions: Post Traumatic Stress Disorder
Interventions: Transcranial Direct Current Stimulator, Written Exposure Therapy; Device · Other
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 70 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: San Antonio, Texas

Search by objective public record fields.

Sarcopenia in Chronic Kidney Disease (CKD) Patients

Tanezumab and Nerve Function In Arthritis Patients

SURPASS Impella 5.5 Study

A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase

A Study to Evaluate the Safety, Tolerability, and Efficacy of Long-Term Gantenerumab Administration in Participants With Alzheimer's Disease (AD)

Prosthetic Fit Assessment in Transtibial Amputees Secondary to Trauma

Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations

A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies

A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)

S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin

S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer

Advent™ Cervical Disc Versus ACDF for Treatment of One Level Degenerative Disc Disease (IDE Study)

Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma

Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs)

MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist

A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)

Study of the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are at Risk for Pregnancy

Vorinostat in Treating Patients With Kidney Cancer

Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

Study of Fluphenazine in Relapsed or Relapsed-and-Refractory Multiple Myeloma

OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events

A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis

Noninvasive Brain Stimulation Combined With Written Exposure Therapy for PTSD in Military Personnel With TBI